Table 2.
Characteristics of cohort participants included in the meta‐analysis
| Characteristic | DCS | GoDARTS | Kosice | PMT1‐EU | PMT2‐EU | Riga | Rotterdam | Sarajevo |
|---|---|---|---|---|---|---|---|---|
| No. of participants | 1,380 | 3,170 | 148 | 125 | 2,358 | 64 | 323 | 87 |
| Age, years | 62.1 ± 10.6 | 61.9 ± 11.1 | 57.5 ± 10.4 | 57.2 ± 12.9 | 66.2 ± 9.8 | 59.7 ± 10.7 | 69.7 ± 10.6 | 58.2 ± 9.0 |
| Sex, male, % | 757 (55) | 1,813 (57) | 72 (49) | 61 (49) | 1,283 (54) | 19 (30) | 147 (46) | 37 (43) |
| BMI, kg/m2 | 30.9 ± 5.2 | 31.7 ± 5.9 | 31.5 ± 4.6 | 37.7 ± 9.1 | 32.3 ± 6.8 | 34.4 ± 5.2 | 29.5 ± 4.7 | 31.2 ± 4.3 |
| Pretreatment HbA1c, % | 7.3 ± 1.3 | 8.9 ± 1.4 | 7.6 ± 1.1 | 7.8 ± 1.3 | 7.8 ± 1.5 | 7.1 ± 1.1 | 7.8 ± 1.3 | 7.8 ± 1.4 |
| On‐treatment HbA1c | 6.6 ± 0.8 | 7.2 ± 1.1 | 7.0 ± 0.8 | 6.7 ± 0.8 | 6.5 ± 0.8 | 6.4 ± 0.5 | 6.7 ± 0.7 | 6.7 ± 0.7 |
| Creatinine clearance, ml/mina | 105 ± 38 | 93.2 ± 35.4 | 104 ± 36 | 80.2 ± 20.1 | 100.0 ± 38.1 | 122.4 ± 44.5 | 85.2 ± 32.6 | 109.5 ± 30.4 |
| Metformin daily dose, mg | 1,089 ± 597 | 1,321 ± 515 | 1,400 ± 540 | 913 ± 326 | 932 ± 490 | 1,704 ± 579 | 800 ± 480 | 1,200 ± 608 |
| Adherence | – | 82.4 ± 16.2 | – | >80b | 88.9 ± 20.4 | – | 79 ± 34 | – |
| Metformin monotherapy, % | 85 | 69 | 100 | 100 | 75 | 100 | 88 | 100 |
BMI, body mass index.
aCreatinine clearance was estimated using the Cockcroft‐Gault formula, except for the PMT1‐EU study in which the MDRD formula was used. bPatients needed to have ≥80% adherence to be included in the study.